Pillsbury Lake Capital LLC Buys Shares of 215,239 MiMedx Group, Inc $MDXG

Pillsbury Lake Capital LLC acquired a new position in shares of MiMedx Group, Inc (NASDAQ:MDXG) in the second quarter, according to its most recent 13F filing with the SEC. The institutional investor acquired 215,239 shares of the company’s stock, valued at approximately $828,670. Pillsbury Lake Capital LLC owned about 0.15% of MiMedx Group at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Paradigm Capital Management Inc. NY acquired a new position in shares of MiMedx Group in the 2nd quarter valued at $15,681,000. Renaissance Technologies LLC lifted its position in shares of MiMedx Group by 22.4% in the first quarter. Renaissance Technologies LLC now owns 3,019,871 shares of the company’s stock worth $11,928,000 after purchasing an additional 552,806 shares in the last quarter. Hillsdale Investment Management Inc. bought a new stake in shares of MiMedx Group in the fourth quarter valued at approximately $7,134,000. Vanguard Group Inc. lifted its position in shares of MiMedx Group by 5.6% in the 4th quarter. Vanguard Group Inc. now owns 7,184,262 shares of the company’s stock worth $48,637,000 after purchasing an additional 382,623 shares during the period. Finally, Dimensional Fund Advisors LP increased its holdings in MiMedx Group by 8.7% during the first quarter. Dimensional Fund Advisors LP now owns 2,694,002 shares of the company’s stock worth $10,640,000 after buying an additional 214,633 shares during the last quarter. Institutional investors and hedge funds own 79.15% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently weighed in on MDXG. Seaport Research Partners cut shares of MiMedx Group to a “neutral” rating in a research note on Monday, August 17th. Cantor Fitzgerald restated an “overweight” rating and set a $8.00 price objective on shares of MiMedx Group in a research note on Monday, August 17th. Raymond James Financial set a $8.00 price objective on shares of MiMedx Group in a research note on Monday, August 17th. Citizens Jmp decreased their price target on MiMedx Group from $7.00 to $6.00 and set a “market outperform” rating for the company in a research note on Thursday, April 30th. Finally, Wall Street Zen downgraded shares of MiMedx Group from a “hold” rating to a “sell” rating in a research note on Saturday, August 1st. Six research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, MiMedx Group currently has an average rating of “Moderate Buy” and an average target price of $8.57.

MiMedx Group Stock Down 0.2%

MiMedx Group stock traded down $0.01 during midday trading on Friday, hitting $4.50. 887,016 shares of the company were exchanged, compared to its average volume of 1,303,331. MiMedx Group, Inc has a fifty-two week low of $3.03 and a fifty-two week high of $7.97. The company has a market cap of $655.92 million, a PE ratio of 112.53 and a beta of 1.45. The company’s fifty day moving average price is $4.17 and its 200-day moving average price is $4.09. The company has a debt-to-equity ratio of 0.07, a current ratio of 5.33 and a quick ratio of 4.79.

MiMedx Group (NASDAQ:MDXG) last released its quarterly earnings data on Wednesday, July 29th. The company reported ($0.05) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.05). MiMedx Group had a return on equity of 12.09% and a net margin of 1.76%.The company had revenue of $64.36 million for the quarter, compared to the consensus estimate of $63.46 million. On average, research analysts predict that MiMedx Group, Inc will post -0.1 EPS for the current fiscal year.

MiMedx Group Profile

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.